AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Fulgent Genetics Soars 16.41% on Q2 Earnings Surge
Generated by AI AgentAinvest Pre-Market Radar
Friday, Aug 1, 2025 8:38 am ET1min read
Aime SummaryFulgent Genetics' stock surged 16.41% in pre-market trading on August 1, 2025, driven by strong financial performance in the second quarter.
Fulgent Genetics reported robust financial results for the second quarter of 2025, with total revenue reaching $81.8 million. Core revenue, a key metric for the company, grew by 16% year-over-year to $81.7 million. This strong performance led the company to raise its full-year 2025 core revenue guidance to $320 million, surpassing analyst expectations.
The company's operational efficiency also improved, with a year-over-year increase in gross margin from 37% to 42% for the three months ended June 30, 2025. This improvement was driven by increased revenue and cost management strategies.
Fulgent Genetics' strong Q2 earnings and positive outlook for the remainder of the year have bolstered investor confidence, contributing to the significant pre-market stock price increase.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Therapeutics shares plunge 5.14% on Dec. 31 2025 due to regulatory and pipeline shifts
Dec.31 2025
Ses AI (NYSE: SES) plunges 6.28% as investors unwind holiday-driven rally gains amid mixed corporate signals.
Dec.31 2025
Novabay Pharmaceuticals Inc (NBY) Surges 27.57% in Pre-Market on December 31 as Small-Cap Biopharma Gains Lead
Dec.31 2025
Dingdong (Cayman) shares plunge 7.09% amid mixed earnings and strategic shifts
Dec.31 2025
Flushing Financial Corp. Plunges 8.94% Amid Renewed Merger Scrutiny
Dec.31 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet